دورية أكاديمية
أعرض في EDS

Antiviral therapies for the management of persistent coronavirus disease 2019 in immunocompromised hosts: A narrative review.

التفاصيل البيبلوغرافية
العنوان: Antiviral therapies for the management of persistent coronavirus disease 2019 in immunocompromised hosts: A narrative review.
المؤلفون: Kinsella PM; Department of Infectious Diseases, Peter MacCallum Cancer Centre, Melbourne, Australia.; Department of Infectious Diseases, University of Melbourne at the Doherty Institute of Infection and Immunity, Melbourne, Australia., Moso MA; Department of Infectious Diseases, University of Melbourne at the Doherty Institute of Infection and Immunity, Melbourne, Australia.; Victorian Infectious Diseases Service, Royal Melbourne Hospital at the Doherty Institute of Infection and Immunity, Melbourne, Australia., Morrissey CO; Department of Infectious Diseases, Alfred Health and Monash University, Melbourne, Australia., Dendle C; Monash Infectious Diseases, Monash Health, Melbourne, Australia.; School of Clinical Sciences, Monash University, Melbourne, Australia., Guy S; Department of Infectious Diseases, Eastern Health, Melbourne, Australia.; Eastern Health Clinical School, Monash University, Melbourne, Australia., Bond K; Department of Microbiology, Royal Melbourne Hospital, Melbourne, Australia.; Victorian Infectious Diseases Reference Laboratory (VIDRL) at the Peter Doherty Institute for Infection and Immunity, Melbourne, Australia.; Department of Microbiology and Immunology, University of Melbourne at the Doherty Institute of Infection and Immunity, Melbourne, Australia., Sasadeusz J; Department of Infectious Diseases, University of Melbourne at the Doherty Institute of Infection and Immunity, Melbourne, Australia.; Victorian Infectious Diseases Service, Royal Melbourne Hospital at the Doherty Institute of Infection and Immunity, Melbourne, Australia., Slavin MA; Department of Infectious Diseases, Peter MacCallum Cancer Centre, Melbourne, Australia.; Victorian Infectious Diseases Service, Royal Melbourne Hospital at the Doherty Institute of Infection and Immunity, Melbourne, Australia.; Sir Peter MacCallum Department of Oncology, Peter MacCallum Cancer Centre, Melbourne, Australia.
المصدر: Transplant infectious disease : an official journal of the Transplantation Society [Transpl Infect Dis] 2024 Jun; Vol. 26 (3), pp. e14301. Date of Electronic Publication: 2024 May 29.
نوع المنشور: Journal Article; Review
اللغة: English
بيانات الدورية: Publisher: Munksgaard Country of Publication: Denmark NLM ID: 100883688 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1399-3062 (Electronic) Linking ISSN: 13982273 NLM ISO Abbreviation: Transpl Infect Dis Subsets: MEDLINE
أسماء مطبوعة: Original Publication: Copenhagen : Munksgaard, c1999-
مواضيع طبية MeSH: Immunocompromised Host* , Antiviral Agents*/therapeutic use , SARS-CoV-2*/immunology , COVID-19*/immunology , COVID-19 Drug Treatment*, Humans ; Drug Therapy, Combination ; Antibodies, Neutralizing/therapeutic use
مستخلص: Antiviral agents with activity against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) have played a critical role in disease management; however, little is known regarding the efficacy of these medications in the treatment of SARS-CoV-2 infection in immunocompromised patients, particularly in the management of persistent SARS-CoV-2 positivity. This narrative review discusses the management of persistent coronavirus disease 2019 in immunocompromised hosts, with a focus on antiviral therapies. We identified 84 cases from the literature describing a variety of approaches, including prolonged antiviral therapy (n = 11), combination antivirals (n = 13), and mixed therapy with antiviral and antibody treatments (n = 60). A high proportion had an underlying haematologic malignancy (n = 67, 80%), and were in receipt of anti-CD20 agents (n = 51, 60%). Success was reported in 70 cases (83%) which varied according to the therapy type. Combination therapies with antivirals may be an effective approach for individuals with persistent SARS-CoV-2 positivity, particularly those that incorporate treatments aimed at increasing neutralizing antibody levels. Any novel approaches taken to this difficult management dilemma should be mindful of the emergence of antiviral resistance.
(© 2024 The Author(s). Transplant Infectious Disease published by Wiley Periodicals LLC.)
References: Tamura T, Yamasoba D, Oda Y, et al. Comparative pathogenicity of SARS‐CoV‐2 Omicron subvariants including BA.1, BA.2, and BA.5. Commun Biol. 2023;6:772.
Suzuki R, Yamasoba D, Kimura I, et al. Attenuated fusogenicity and pathogenicity of SARS‐CoV‐2 Omicron variant. Nature. 2022;603:700‐705.
Avery RK, Chiang TP‐Y, Marr KA, et al. Inpatient COVID‐19 outcomes in solid organ transplant recipients compared to non‐solid organ transplant patients: A retrospective cohort. Am J Transplant. 2021;21:2498‐2508.
Cochran W, Shah P, Barker L, et al. COVID‐19 clinical outcomes in solid organ transplant recipients during the Omicron surge. Transplantation. 2022;106:e346‐e347.
Langerbeins P, Hallek M. COVID‐19 in patients with hematologic malignancy. Blood. 2022;140:236‐252.
Blennow O, Salmanton‐García J, Nowak P, et al. Outcome of infection with omicron SARS‐CoV‐2 variant in patients with hematological malignancies: An EPICOVIDEHA survey report. Am J Hematol. 2022;97:E312‐E317.
Januel E, Hajage D, Labauge P, et al. Association between anti‐CD20 therapies and COVID‐19 severity among patients with relapsing‐remitting and progressive multiple sclerosis. JAMA Netw Open. 2023;6:e2319766.
DeVoe C, Pandey S, Shariff D, et al. COVID‐19 in vaccinated versus unvaccinated hematologic malignancy patients. Transpl Infect Dis. 2022;24:e13835.
Trøseid M, Hentzien M, Ader F, et al. Immunocompromised patients have been neglected in COVID‐19 trials: a call for action. Clin Microbiol Infect. 2022;28:1182‐1183.
Dioverti V, Salto‐Alejandre S, Haidar G. Immunocompromised patients with protracted COVID‐19: a review of “long persisters”. Curr Transplant Rep. 2022;9:209‐218.
Gliga S, Lübke N, Killer A, et al. Rapid selection of sotrovimab escape variants in severe acute respiratory syndrome coronavirus 2 Omicron‐infected immunocompromised patients. Clin Infect Dis. 2023;76:408‐415.
Hall VG, Sim BZ, Lim C, et al. COVID‐19 infection among patients with cancer in Australia from 2020 to 2022: a national multicentre cohort study. Lancet Reg Health West Pac. 2023;38:100824. Accessed August 29, 2023. Available at: https://www.thelancet.com/journals/lanwpc/article/PIIS2666‐6065(23)00142‐6/fulltext#secsectitle0010.
Longo BM, Venuti F, Gaviraghi A, et al. Sequential or combination treatments as rescue therapies in immunocompromised patients with persistent SARS‐CoV‐2 infection in the Omicron era: a case series. Antibiotics. 2023;12:1460.
Hettle D, Hutchings S, Muir P, Moran E. Persistent SARS‐CoV‐2 infection in immunocompromised patients facilitates rapid viral evolution: Retrospective cohort study and literature review. Clin Infect Pract. 2022;16:100210.
Lee CY, Shah MK, Hoyos D, et al. Prolonged SARS‐CoV‐2 infection in patients with lymphoid malignancies. Cancer Discov. 2022;12:62‐73.
Nguyen THO, Rowntree LC, Allen LF, et al. Robust SARS‐CoV‐2 T cell responses with common TCRαβ motifs toward COVID‐19 vaccines in patients with hematological malignancy impacting B cells. Cell Reports Med. 2023;4:101017.
Chan M, Linn MMN, O'Hagan T, et al. Persistent SARS‐CoV‐2 PCR positivity despite anti‐viral treatment in immunodeficient patients. J Clin Immunol. 2023;43(6):1083‐1092.
Li Y, Choudhary MC, Regan J, et al. SARS‐CoV‐2 viral clearance and evolution varies by type and severity of immunodeficiency. Sci Transl Med. 2024;16:eadk1599.
Orth HM, Flasshove C, Berger M, et al. Early combination therapy of COVID‐19 in high‐risk patients. Infection. Published online: November 29, 2023. Accessed March 10, 2024. Available at: doi:10.1007/s15010‐023‐02125‐5.
Phadke VK, Scanlon N, Jordan SC, Rouphael NG. Immune responses to SARS‐CoV‐2 in solid organ transplant recipients. Curr Transplant Rep. 2021;8:127‐139.
Thieme CJ, Anft M, Paniskaki K, et al. The magnitude and functionality of SARS‐CoV‐2 reactive cellular and humoral immunity in transplant population is similar to the general population despite immunosuppression. Transplantation. 2021;105:2156.
Raglow Z, Surie D, Chappell JD, et al. SARS‐CoV‐2 shedding and evolution in patients who were immunocompromised during the omicron period: a multicentre, prospective analysis. Lancet Microbe. 2024;5(3):e235‐e246. Accessed March 5, 2024. Available at: https://www.thelancet.com/journals/lanmic/article/PIIS2666‐5247(23)00336‐1/fulltext#appsec1.
Gottlieb RL, Vaca CE, Paredes R, et al. Early Remdesivir to prevent progression to severe COVID‐19 in outpatients. N Engl J Med. 2022;386:305‐315.
Ader F, Bouscambert‐Duchamp M, Hites M, et al. Remdesivir plus standard of care versus standard of care alone for the treatment of patients admitted to hospital with COVID‐19 (DisCoVeRy): a phase 3, randomised, controlled, open‐label trial. Lancet Infect Dis. 2022;22:209‐221.
Mehta RM, Bansal S, Bysani S, Kalpakam H. A shorter symptom onset to remdesivir treatment (SORT) interval is associated with a lower mortality in moderate‐to‐severe COVID‐19: A real‐world analysis. Int J Infect Dis. 2021;106:71‐77.
Beigel JH, Tomashek KM, Dodd LE, et al. Remdesivir for the treatment of COVID‐19 ‐ final report. N Engl J Med. 2020;383:1813‐1826.
Ali K, Azher T, Baqi M, et al. Remdesivir for the treatment of patients in hospital with COVID‐19 in Canada: a randomized controlled trial. CMAJ. 2022;194:E242‐E251.
WHO Solidarity Trial Consortium. Remdesivir and three other drugs for hospitalised patients with COVID‐19: final results of the WHO Solidarity randomised trial and updated meta‐analyses. Lancet. 2022;399:1941‐1953.
Spinner CD, Gottlieb RL, Criner GJ, et al. Effect of Remdesivir vs standard care on clinical status at 11 days in patients with moderate COVID‐19: a randomized clinical trial. JAMA. 2020;324:1048‐1057.
Goldman JD, Lye DCB, Hui DS, et al. Remdesivir for 5 or 10 days in patients with severe COVID‐19. N Engl J Med. 2020;383:1827‐1837.
Fesu D, Bohacs A, Hidvegi E, et al. Remdesivir in Solid Organ Recipients for COVID‐19 Pneumonia. Transplant Proc. 2022;54:2567‐2569.
Aksak‐Wąs BJ, Chober D, Serwin K, et al. Remdesivir reduces mortality in hemato‐oncology patients with COVID‐19. JIR. 2022;15:4907‐4920.
Jayk Bernal A, Gomes da Silva MM, Musungaie DB, et al. Molnupiravir for oral treatment of COVID‐19 in nonhospitalized patients. N Engl J Med. 2022;386:509‐520.
Butler CC, Hobbs FDR, Gbinigie OA, et al. Molnupiravir plus usual care versus usual care alone as early treatment for adults with COVID‐19 at increased risk of adverse outcomes (PANORAMIC): an open‐label, platform‐adaptive randomised controlled trial. Lancet. 2023;401:281‐293.
The Lancet Infectious Diseases. Unmet need for COVID‐19 therapies in community settings. Lancet Infect Dis. 2021;21:1471.
Johnson MG, Strizki JM, Brown ML, et al. Molnupiravir for the treatment of COVID‐19 in immunocompromised participants: efficacy, safety, and virology results from the phase 3 randomized, placebo‐controlled MOVe‐OUT trial. Infection. 2023;51:1273‐1284. Available at: doi:10.1007/s15010‐022‐01959‐9.
Kaboré J‐L, Laffont B, Diop M, et al. Real‐world effectiveness of nirmatrelvir/ritonavir on coronavirus disease 2019 (COVID‐19)–associated hospitalization prevention: a population‐based cohort study in the province of Quebec, Canada. Clin Infect Dis. 2023:ciad287.
Najjar‐Debbiny R, Gronich N, Weber G, et al. Effectiveness of paxlovid in reducing severe coronavirus disease 2019 and mortality in high‐risk patients. Clin Infect Dis. 2023;76:e342‐e349.
Sun F, Lin Y, Wang X, Gao Y, Ye S. Paxlovid in patients who are immunocompromised and hospitalised with SARS‐CoV‐2 infection. Lancet Infect Dis. 2022;22:1279.
Liu J, Pan X, Zhang S, et al. Efficacy and safety of Paxlovid in severe adult patients with SARS‐Cov‐2 infection: a multicenter randomized controlled study. Lancet Reg Health West Pac. 2023;33:100694. Accessed June 24, 2023. Available at: https://www.thelancet.com/journals/lanwpc/article/PIIS2666‐6065(23)00012‐3/fulltext#secsectitle0120.
Fishbane S, Hirsch JS, Nair V. Special considerations for paxlovid treatment among transplant recipients with SARS‐CoV‐2 infection. Am J Kidney Dis. 2022;79:480‐482.
Ritonavir‐boosted Nirmatrelvir (Paxlovid). Accessed June 1, 2023. Available at: https://www.covid19treatmentguidelines.nih.gov/therapies/antivirals‐including‐antibody‐products/ritonavir‐boosted‐nirmatrelvir–paxlovid‐/.
Yan VC. Test of 5‐ versus 10‐day Remdesivir treatment in immunocompromised patients with coronavirus disease 2019. Clin Infect Dis. 2023;76:1154‐1155.
Breeden M, Aitken SL, Baang JH, et al. Successful treatment of prolonged severe acute respiratory syndrome coronavirus 2 infection in patients with immunodeficiency with extended Nirmatrelvir/Ritonavir: case series. Open Forum Infect Dis. 2023;10:ofad189.
Ambati S, Ali B, Seddon O, et al. Resolution of persistent SARS‐CoV‐2 infection with prolonged intravenous remdesivir and vaccination in a patient post CAR‐T. Int J Hematol. 2023;117:765‐768.
Li P, Wang Y, Lavrijsen M, et al. SARS‐CoV‐2 Omicron variant is highly sensitive to molnupiravir, nirmatrelvir, and the combination. Cell Res. 2022;32:322‐324.
Abdelnabi R, Foo CS, Kaptein SJF, et al. The combined treatment of Molnupiravir and Favipiravir results in a potentiation of antiviral efficacy in a SARS‐CoV‐2 hamster infection model. EBioMedicine. 2021;72:103595.
Jeong JH, Chokkakula S, Min SC, et al. Combination therapy with nirmatrelvir and molnupiravir improves the survival of SARS‐CoV‐2 infected mice. Antiviral Res. 2022;208:105430.
Gidari A, Sabbatini S, Schiaroli E, et al. The combination of Molnupiravir with Nirmatrelvir or GC376 has a synergic role in the inhibition of SARS‐CoV‐2 replication in vitro. Microorganisms. 2022;10:1475.
Schultz DC, Johnson RM, Ayyanathan K, et al. Pyrimidine inhibitors synergize with nucleoside analogues to block SARS‐CoV‐2. Nature. 2022;604:134‐140.
Focosi D, McConnell S, Shoham S, Casadevall A, Maggi F, Antonelli G. Nirmatrelvir and COVID‐19: development, pharmacokinetics, clinical efficacy, resistance, relapse, and pharmacoeconomics. Int J Antimicrob Agents. 2023;61:106708.
Hogan JI, Duerr R, Dimartino D, et al. Remdesivir resistance in transplant recipients with persistent coronavirus disease 2019. Clin Infect Dis. 2023;76:342‐345.
Brosh‐Nissimov T, Ma'aravi N, Leshin‐Carmel D, et al. Combination treatment of persistent COVID‐19 in immunocompromised patients with remdesivir, nirmaltrevir/ritonavir and tixegavimab/cilgavimab. 2023:2023.04.07.23288144. Accessed June 25, 2023. Available at: https://www.medrxiv.org/content/10.1101/2023.04.07.23288144v1.
Toussi SS, Hammond JL, Gerstenberger BS, Anderson AS. Therapeutics for COVID‐19. Nat Microbiol. 2023;8:771‐786.
Chen L, Zody MC, Di Germanio C, et al. Emergence of multiple SARS‐CoV‐2 antibody escape variants in an immunocompromised host undergoing convalescent plasma treatment. mSphere. 2021;6:e0048021.
Łyżwa E, Sobiecka M, Lewandowska K, et al. Prolonged SARS‐CoV‐2 infection and organizing pneumonia in a patient with follicular lymphoma, treated with obinutuzumab—challenging recognition and treatment. Viruses. 2023;15:693.
Lanzafame M, Gottardi M, Guella L, et al. Successful treatment of persistent SARS‐CoV‐2 infection with nirmatrelvir/ritonavir plus sotrovimab in four immunocompromised patients. J Chemother. 2023;0:1‐4.
Wada D, Nakamori Y, Maruyama S, et al. Novel treatment combining antiviral and neutralizing antibody‐based therapies with monitoring of spike‐specific antibody and viral load for immunocompromised patients with persistent COVID‐19 infection. Exp Hematol Oncol. 2022;11:1‐4.
Mikulska M, Sepulcri C, Dentone C, et al. Triple combination therapy with 2 antivirals and monoclonal antibodies for persistent or relapsed severe acute respiratory syndrome coronavirus 2 infection in immunocompromised patients. Clin Infect Dis. 2023;77(2):280‐286.
Huygens S, Gharbharan A, Serroukh Y, et al. High‐titer convalescent plasma plus nirmatrelvir/ritonavir treatment for non‐resolving COVID‐19 in six immunocompromised patients. J Antimicrob Chemother. 2023;78(7):1644‐1648.
Upasani V, Townsend K, Wu MY, et al. Commercial immunoglobulin products contain neutralising antibodies against SARS‐CoV‐2 spike protein. Clin Infect Dis. 2023;77(7):950‐960.
Brown L‐AK, Moran E, Goodman A, et al. Treatment of chronic or relapsing COVID‐19 in immunodeficiency. J Allergy Clin Immunol. 2022;149:557‐561.e1.
Choi B, Choudhary MC, Regan J, et al. Persistence and evolution of SARS‐CoV‐2 in an immunocompromised host. N Engl J Med. 2020;383:2291‐2293.
Andrés C, González‐Sánchez A, Jiménez M, et al. Emergence of Delta and Omicron variants carrying resistance‐associated mutations in immunocompromised patients undergoing sotrovimab treatment with long‐term viral excretion. Clin Microbiol Infect. 2023;29:240‐246.
Tzou PL, Tao K, Pond SLK, Shafer RW. Coronavirus Resistance Database (CoV‐RDB): SARS‐CoV‐2 susceptibility to monoclonal antibodies, convalescent plasma, and plasma from vaccinated persons. PLoS One. 2022;17:e0261045.
Shannon A, Canard B. Kill or corrupt: Mechanisms of action and drug‐resistance of nucleotide analogues against SARS‐CoV‐2. Antiviral Res. 2023;210:105501.
Martinot M, Jary A, Fafi‐Kremer S, et al. Emerging RNA‐dependent RNA polymerase mutation in a remdesivir‐treated B‐cell immunodeficient patient with protracted coronavirus disease 2019. Clin Infect Dis. 2021;73:e1762‐e1765.
Gandhi S, Klein J, Robertson AJ, et al. De novo emergence of a remdesivir resistance mutation during treatment of persistent SARS‐CoV‐2 infection in an immunocompromised patient: a case report. Nat Commun. 2022;13:1547.
Szemiel AM, Merits A, Orton RJ, et al. In vitro selection of Remdesivir resistance suggests evolutionary predictability of SARS‐CoV‐2. PLoS Pathog. 2021;17:e1009929.
Zuckerman NS, Bucris E, Keidar‐Friedman D, Amsalem M, Brosh‐Nissimov T. Nirmatrelvir resistance‐de novo E166V/L50V mutations in an immunocompromised patient treated with prolonged nirmatrelvir/ritonavir monotherapy leading to clinical and virological treatment failure‐a case report. Clin Infect Dis. 2024;78:352‐355.
Iketani S, Mohri H, Culbertson B, et al. Multiple pathways for SARS‐CoV‐2 resistance to nirmatrelvir. Nature. 2023;613:558‐564.
Zhou Y, Gammeltoft KA, Ryberg LA, et al. Nirmatrelvir‐resistant SARS‐CoV‐2 variants with high fitness in an infectious cell culture system. Sci Adv. 2022;8:eadd7197.
Tian L, Pang Z, Li M, et al. Molnupiravir and its antiviral activity against COVID‐19. Front Immunol. 2022;13:855496. Accessed August 10, 2023. Available at: https://www.frontiersin.org/articles/10.3389/fimmu.2022.855496.
Sheahan TP, Sims AC, Zhou S, et al. An orally bioavailable broad‐spectrum antiviral inhibits SARS‐CoV‐2 in human airway epithelial cell cultures and multiple coronaviruses in mice. Sci Transl Med. 2020;12:eabb5883.
World Health Organization. Living guidance for clinical management of COVID‐19. Accessed August 10, 2023. Available at: https://www.who.int/publications‐detail‐redirect/WHO‐2019‐nCoV‐clinical‐2021‐2.
National Institutes of Health. Special Considerations in People Who Are Immunocompromised. Accessed June 2, 2023. Available at: https://www.covid19treatmentguidelines.nih.gov/special‐populations/immunocompromised/.
Moso MA, Sasadeusz J, Morrissey CO, et al. Survey of treatment practices for immunocompromised patients with COVID‐19 in Australasia. Intern Med J. 2023;53:619‐624.
FAQs for Organ Transplantation. 2021. Accessed March 3, 2024. Available at: https://www.myast.org/faqs‐organ‐transplantation.
Graziani L, Gori L, Manciulli T, et al. Successful use of nirmatrelvir/ritonavir in immunocompromised patients with persistent and/or relapsing COVID‐19. J Antimicrob Chemother. 2023;78:555‐558.
Martinez MA, Chen T‐Y, Choi H, et al. Extended Remdesivir infusion for persistent coronavirus disease 2019 infection. Open Forum Infect Dis. 2022;9:ofac382.
Lindahl AL, Ahava MJ, Haukipää M, Kreivi H‐R, Lipponen A, Kortela E. Successful treatment of persisting SARS‐CoV‐2 infection in an immunocompromised patient with repeated nirmatrelvir/ritonavir courses: a case report. Infect Dis. 2023;55:585‐589.
Liu C, Yoke LH, Bhattacharyya P, et al. Successful treatment of persistent symptomatic coronavirus disease 19 infection with extended‐duration nirmatrelvir‐ritonavir among outpatients with hematologic cancer. Open Forum Infect Dis. 2023;10:ofad306.
Dentone C, Mikulska M, Sepulcri C, et al. Triple antiviral treatment for COVID‐19 in an immunocompromised patient. J Antimicrob Chemother. 2023;78(8):2097‐2099.
Marangoni D, Antonello RM, Coppi M, et al. Combination regimen of nirmatrelvir/ritonavir and molnupiravir for the treatment of persistent SARS‐CoV‐2 infection: a case report and a scoping review of the literature. Int J Infect Dis. 2023;133:53‐56.
Trottier CA, Wong B, Kohli R, et al. Dual antiviral therapy for persistent coronavirus disease 2019 and associated organizing pneumonia in an immunocompromised host. Clin Infect Dis. 2023;76:923‐925.
Blennow O, Vesterbacka J, Tovatt T, Nowak P. Successful combination treatment for persistent severe acute respiratory syndrome coronavirus 2 infection. Clin Infect Dis. 2023;76:1864‐1865.
Ford ES, Simmons W, Karmarkar EN, et al. Successful Treatment of prolonged, severe coronavirus disease 2019 lower respiratory tract disease in a B cell acute lymphoblastic leukemia patient with an extended course of remdesivir and nirmatrelvir/ritonavir. Clin Infect Dis. 2023;76:926‐929.
Faxén L, Edvinsson M. Persistent SARS‐CoV‐2 infection in patients with B‐cell deficiency: a case series of successful antiviral treatment of four patients. Ups J Med Sci. 2023;128. doi:10.48101/ujms.v128.9807.
Segura Fábrega A, Pérez Catalán I, Gómez Alfaro I, et al. Association of nirmatrelvir/ritonavir and remdesivir as treatment for SARS‐CoV‐2 infection in immunocompromised patients with hematologic malignancies. Series of four cases. Rev Esp Quimioter. 2023;36:655‐657.
Rizzo A, Foschi A, Bracchitta F, et al. Persistent detection and sequencing of SARS‐CoV‐2 in the bloodstream of an immunocompromised patient. J Med Virol. 2023;95:e28381.
Ko KKK, Yingtaweesittikul H, Tan TT, et al. Emergence of SARS‐CoV‐2 Spike Mutations during Prolonged Infection in Immunocompromised Hosts. Microbiol Spectr. 2022;10:e0079122.
Ertesvåg NU, Sakkestad ST, Zhou F, et al. Persistent fever and positive PCR 90 Days Post‐SARS‐CoV‐2 infection in a rituximab‐treated patient: a case of late antiviral treatment. Viruses. 2022;14:1757.
Kintrilis N, Gkinos CP, Galinos I. Prolonged COVID‐19 in a multiple sclerosis patient treated with rituximab. Cureus. 2022;14(12):e32523.
Mendel A, Colmegna I, Bourque G, et al. More than a ‘Hundred Days War’: Persistent SARS‐CoV‐2 infection in a patient with ANCA‐associated vasculitis. J Assoc Med Microbiol Infect Dis Can. 2022;7:131‐134.
Palomba E, Carrabba M, Zuglian G, et al. Treatment of SARS‐CoV‐2 relapse with remdesivir and neutralizing antibodies cocktail in a patient with X‐linked agammaglobulinaemia. Int J Infect Dis. 2021;110:338‐340.
Baang JH, Smith C, Mirabelli C, et al. Prolonged severe acute respiratory syndrome coronavirus 2 replication in an immunocompromised patient. J Infect Dis. 2021;223(1):23‐27.
Martínez‐Barranco P, García‐Roa M, Trelles‐Martínez R, et al. Management of persistent SARS‐CoV‐2 infection in patients with follicular lymphoma. Acta Haematol. 2022;145(4):384‐393.
Lazzari L, Oltolini C, Ciceri F, Giglio F. Complicated and persistent severe COVID‐19 pneumonia in a recipient of allogeneic haematopoietic stem cell transplant. BMJ Case Reports CP. 2021;14:e245992.
Vita S, D'Abramo A, Coppola A, et al. Combined antiviral therapy as effective and feasible option in allogenic hematopoietic stem cell transplantation during SARS‐COV‐2 infection: a case report. Front Oncol. 2024;14:1290614.
Iwasaki M, Hashimoto M, Takeuchi JS, et al. Relapse of COVID‐19 and viral evolution in a patient with good syndrome: a case report. Cureus. 2024;16:e52592.
Maruki T, Nomoto H, Iwamoto N, et al. Successful management of persistent COVID‐19 using combination antiviral therapy (nirmatrelvir/ritonavir and remdesivir) and intravenous immunoglobulin transfusion in an immunocompromised host who had received CD20 depleting therapy for follicular lymphoma. J Infect Chemother. 2024:S1341‐321X(24)00012–6.
Yanagihara T, Kadowaki M, Otsuka J, et al. A teaching case: persistent COVID‐19 pneumonia resembling cryptogenic organizing pneumonia in a patient with remitted lymphoma. Cureus. 2023;15:e48319.
Zhu W, Xie T, Xu M, Chen R, Zhang T. Migratory pulmonary infiltrates in a B‐cell‐depleted COVID‐19 patient. Infect Drug Resist. 2023;16:7205‐7208.
Bez P, D'ippolito G, Deiana CM, et al. Struggling with COVID‐19 in adult inborn errors of immunity patients: a case series of combination therapy and multiple lines of therapy for selected patients. Life. 2023;13:1530.
Kemp SA, Collier DA, Datir RP, et al. SARS‐CoV‐2 evolution during treatment of chronic infection. Nature. 2021;592:277‐282.
Nagai H, Saito M, Adachi E, et al. Casirivimab/Imdevimab for active COVID‐19 pneumonia which persisted for nine months in a patient with follicular lymphoma during anti‐CD20 therapy. Jpn J Infect Dis. 2022;75:608‐611.
Dioverti MV, Gaston DC, Morris CP, et al. Combination therapy with Casirivimab/Imdevimab and Remdesivir for protracted SARS‐CoV‐2 infection in B‐cell‐depleted patients. Open Forum Infect Dis. 2022;9:ofac064.
فهرسة مساهمة: Keywords: SARS‐CoV‐2; antibody; antiviral; immunocompromised; persistent; prolonged
المشرفين على المادة: 0 (Antiviral Agents)
0 (Antibodies, Neutralizing)
تواريخ الأحداث: Date Created: 20240529 Date Completed: 20240618 Latest Revision: 20240625
رمز التحديث: 20240626
DOI: 10.1111/tid.14301
PMID: 38809102
قاعدة البيانات: MEDLINE
الوصف
تدمد:1399-3062
DOI:10.1111/tid.14301